You need JavaScript to view this

Inhibition effects of {sup 125}I-triplex forming oligonucleotide to hepatoma cells

Journal Article:

Abstract

Objective: Triplex forming oligonucleotide (TFO) has been reported as a new antigene strategy. The purpose of this study was to observe the inhibition effects of {sup 125}I-TFO on hepatoma cells and to investigate the possibility of using {sup 125}I-TFO as an antigene radiotherapy technique for hepatocellular carcinoma (HCC) related to HBV. Methods: TFO complementary to the initiator of S gene of HBV was synthesized and labeled with {sup 125}I. HepG2.2.15 cells, in which HBV genome was integrated, were incubated with {sup 125}I-TFO, TFO and {sup 125}I respectively. After incubation, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) of each group were assayed with ELISA and the survival rate of cells in each group was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-trazolium bromide (MTT) reduction assay. Results: {sup 125}I-TFO showed a high stability with a radiolabeling rate of >93%. The radiochemical purity of labeled compound was 90.8%, 81.1% and 73.2% respectively after 12, 48 and 72 h at 37 degree C. The peak inhibition effect of {sup 125}I-TFO on synthesizing HBsAg and HBeAg by HepG2.2.15 cells were found at 48 h after transfection, with significantly the highest inhibition rate of 45.2% for HBsAg and 74.5% for HBeAg expression among the three groups(P<0.01  More>>
Authors:
Zhongwei, Lv; Min, Hou; Haidong, Cai; Xueyu, Yuan; Yuehua, Yang; Shidong, Yuan; [1]  Junmin, He
  1. Department of Nuclear Medicine, 10th People's Hospital, Tongji Univ., Shanghai (China)
Publication Date:
Aug 15, 2007
Product Type:
Journal Article
Resource Relation:
Journal Name: Chinese Journal of Nuclear Medicine; Journal Volume: 27; Journal Issue: 4; Other Information: 1 tab., 13 refs
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANTIGENS; ENZYME IMMUNOASSAY; GENES; GROWTH; HEPATITIS; HEPATOMAS; IMPURITIES; INCUBATION; INHIBITION; IODINE 125; LABELLING; OLIGONUCLEOTIDES; RADIOPHARMACEUTICALS; RADIOTHERAPY; STABILITY; SURVIVAL CURVES; SYNTHESIS; TUMOR CELLS; VIRUSES
OSTI ID:
21206094
Country of Origin:
China
Language:
Chinese
Other Identifying Numbers:
Journal ID: ISSN 0253-9780; CITCDE; TRN: CN0901856076646
Submitting Site:
INIS
Size:
page(s) 218-220
Announcement Date:
Sep 02, 2009

Journal Article:

Citation Formats

Zhongwei, Lv, Min, Hou, Haidong, Cai, Xueyu, Yuan, Yuehua, Yang, Shidong, Yuan, and Junmin, He. Inhibition effects of {sup 125}I-triplex forming oligonucleotide to hepatoma cells. China: N. p., 2007. Web.
Zhongwei, Lv, Min, Hou, Haidong, Cai, Xueyu, Yuan, Yuehua, Yang, Shidong, Yuan, & Junmin, He. Inhibition effects of {sup 125}I-triplex forming oligonucleotide to hepatoma cells. China.
Zhongwei, Lv, Min, Hou, Haidong, Cai, Xueyu, Yuan, Yuehua, Yang, Shidong, Yuan, and Junmin, He. 2007. "Inhibition effects of {sup 125}I-triplex forming oligonucleotide to hepatoma cells." China.
@misc{etde_21206094,
title = {Inhibition effects of {sup 125}I-triplex forming oligonucleotide to hepatoma cells}
author = {Zhongwei, Lv, Min, Hou, Haidong, Cai, Xueyu, Yuan, Yuehua, Yang, Shidong, Yuan, and Junmin, He}
abstractNote = {Objective: Triplex forming oligonucleotide (TFO) has been reported as a new antigene strategy. The purpose of this study was to observe the inhibition effects of {sup 125}I-TFO on hepatoma cells and to investigate the possibility of using {sup 125}I-TFO as an antigene radiotherapy technique for hepatocellular carcinoma (HCC) related to HBV. Methods: TFO complementary to the initiator of S gene of HBV was synthesized and labeled with {sup 125}I. HepG2.2.15 cells, in which HBV genome was integrated, were incubated with {sup 125}I-TFO, TFO and {sup 125}I respectively. After incubation, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) of each group were assayed with ELISA and the survival rate of cells in each group was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-trazolium bromide (MTT) reduction assay. Results: {sup 125}I-TFO showed a high stability with a radiolabeling rate of >93%. The radiochemical purity of labeled compound was 90.8%, 81.1% and 73.2% respectively after 12, 48 and 72 h at 37 degree C. The peak inhibition effect of {sup 125}I-TFO on synthesizing HBsAg and HBeAg by HepG2.2.15 cells were found at 48 h after transfection, with significantly the highest inhibition rate of 45.2% for HBsAg and 74.5% for HBeAg expression among the three groups(P<0.01 ). As the transfection time prolonged its inhibition effects were stronger. Conclusion: {sup 125}I-TFO may inhibit the antigen expression of HBV and the growth of hepatocarcinoma cells, thus it may provide a new approach to develop gene-based radiotherapeutic pharmaceuticals for anti-HBV and HCC. (authors)}
journal = {Chinese Journal of Nuclear Medicine}
issue = {4}
volume = {27}
place = {China}
year = {2007}
month = {Aug}
}